Skip to main content
Michael Schweizer, MD, Oncology, Seattle, WA

Michael Thomas Schweizer MD

Genitourinary Oncology, Hematologic Oncology


Associate Professor of Medicine, University of Washington

Join to View Full Profile
  • 825 Eastlake Ave ESeattle, WA 98109

  • Phone+1 206-288-1000

Dr. Schweizer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2008 - 2011
  • Lewis Katz School of Medicine at Temple University
    Lewis Katz School of Medicine at Temple UniversityClass of 2008

Certifications & Licensure

  • AK State Medical License
    AK State Medical License 2022 - 2026
  • WA State Medical License
    WA State Medical License 2014 - 2025
  • MD State Medical License
    MD State Medical License 2011 - 2015
  • IL State Medical License
    IL State Medical License 2008 - 2011
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Clonal Hematopoiesis in DNA Repair Genes with Prostate Cancer Plasma Cell-Free DNA Testing Interference  
    Michael T Schweizer, Petros Grivas, Heather H Cheng, Evan Y Yu, JAMA Oncology

Lectures

  • Genomic characterization of ductal adenocarcinoma of the prostate. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Mevrometostat Combo Posts Strong Data in Early-Phase Prostate Cancer Trial
    Mevrometostat Combo Posts Strong Data in Early-Phase Prostate Cancer TrialFebruary 21st, 2025
  • Radiographic PFS in Metastatic CRPC More Than Doubles with Novel Combination
    Radiographic PFS in Metastatic CRPC More Than Doubles with Novel CombinationFebruary 13th, 2025
  • Fred Hutch at ASCO: Progress in Treating Metastatic Cancer, Hospice Access for Cancer Patients, Use of Machine Learning with CAR T-cell Therapy
    Fred Hutch at ASCO: Progress in Treating Metastatic Cancer, Hospice Access for Cancer Patients, Use of Machine Learning with CAR T-cell TherapyMay 23rd, 2024
  • Join now to see all

Grant Support

  • Augmenting PSMA expression to enhance PSMA directed therapeutic efficacyFRED HUTCHINSON CANCER CENTER2024–2029
  • Augmenting PSMA expression to enhance PSMA directed therapeutic efficacyFRED HUTCHINSON CANCER CENTER2024–2029

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: